Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

被引：15

作者：

Barth, T. ^{[1
]}

Zeman, F. ^{[2
]}

Helbig, H. ^{[1
]}

Gamulescu, M. -A. ^{[1
]}

机构：

[1] Univ Med Ctr Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany

[2] Univ Med Ctr Regensburg, Ctr Clin Studies ZKS, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany

来源：

INTERNATIONAL OPHTHALMOLOGY | 2018年 / 38卷 / 03期

关键词：

Choroidal neovascularization; Punctate inner choroidopathy; Intravitreal antiangiogenic therapy; Anti-VEGF (vascular endothelial growth factor); OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; SURGICAL-MANAGEMENT; CLINICAL-FEATURES; CASE SERIES; BEVACIZUMAB; RANIBIZUMAB; RESOLUTION;

D O I：

10.1007/s10792-017-0536-0

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Delta +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Delta -4.3 lines). CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.

引用

页码：923 / 931

页数：9

共 32 条

[21] Surgical management and ultrastructural study of choroidal neovascularization in punctate inner choroidopathy after bevacizumab [J].